Ratings for Lineage Cell Therapeutics (AMEX:LCTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...
7 analysts have shared their evaluations of Lineage (NASDAQ:LINE) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of ...
In recent news, several law firms announced that class action lawsuits have been filed against Lineage, Inc. following its July 2024 IPO, alleging the company made materially false or misleading ...
In the latest quarter, 7 analysts provided ratings for Lineage (NASDAQ:LINE), showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results